Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Genetic Counseling
Published in: Journal of Genetic Counseling 2/2010

01-04-2010 | Professional Issues

Prenatal Testing for Down Syndrome: Comparison of Screening Practices in the UK and USA

Author: Dagmar Tapon

Published in: Journal of Genetic Counseling | Issue 2/2010

Login to get access

Abstract

Prenatal testing for Down Syndrome is a topic covered in every genetic counselor’s training as it constitutes the main workload of genetic counselors in prenatal settings. Most Western countries nowadays offer some type of testing for Down Syndrome. However, practices vary according to country with regards to what tests are offered, insurance coverage and the legal situation concerning the option of terminating an affected pregnancy. In view of the growing interest in international genetic counseling issues, this article aims to compare prenatal testing practices in two English-speaking countries: the United Kingdom and the United States of America. A case will be presented to highlight some of the differences in practice. The topic underlines important implications for genetic counseling practice, such as patients’ understanding of testing practices, risk perception, counseling provision and impact of prenatal testing results.
Literature
Ahmed, S., Bryant, L., & Hewison, J. (2007). ‘Balance’ is in the eye of the beholder: providing information to support informed choices in antenatal screening via Antenatal Screening Web Resource. Health Expectations, 10, 309–320.PubMedPubMedCentralCrossRef
Alderson, P. (2001). Down’s syndrome: cost, quality and value of life. Social Science and Medicine, 53(5), 627–638.PubMedCrossRef
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 77. (2007a). Screening for fetal chromosomal abnormalities. Obstetrics and Gynecology, 109, 217–228.CrossRef
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88. (2007b). Invasive prenatal testing for aneuploidy. Obstetrics and Gynecology, 110(6), 1459–1467.CrossRef
American College of Obstetricians and Gynecologists. ACOG Committee on Ethics, Committee Opinion No. 360. (2007d). Sex selection. Obstetrics and Gynecology, 109(2 Pt 1), 475–478.
Ball, R. H., Caughey, A. B., Malone, F. D., First and Second Trimester Evaluation of Risk (FASTER) Research Consortium, et al. (2007). First- and second-trimester evaluation of risk for Down syndrome. Obstetrics and Gynecology, 110, 10–17.PubMedCrossRef
Benacerraf, B. R. (2005). The role of the second trimester genetic sonogram in screening for fetal Down syndrome. Seminars in Perinatology, 29(6), 386–394.PubMedCrossRef
Benn, P. A., Campbell, W. A., Zelop, C. M., Ingardia, C., & Egan, J. F. (2007). Stepwise sequential screening for fetal aneuploidy. American Journal of Obstetrics and Gynecology, 197(3), 312.PubMedCrossRef
Bersinger, N. A., Zakher, A., Huber, U., Pescia, G., & Schneider, H. (1995). A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies. Archives of Gynecology and Obstetrics, 256(4), 185–192.PubMedCrossRef
Bianchi, D. W. (1999). Fetal cells in the maternal circulation: feasibility for prenatal diagnosis. British Journal Haematology, 105, 574–583.CrossRef
Bishop, A. J., Marteau, T. M., Armstrong, D., Chitty, L. S., Longworth, L., Buxton, M. J., et al. (2004). Women and health care professionals’ preferences for Down’s Syndrome screening tests: a conjoint analysis study. BJOG, 111(8), 775–779.PubMedCrossRef
Bogart, M., Pandian, M. R., & Jones, O. W. (1987). Abnormal maternal serum chorionic gonadotrophin levels in pregnancies with fetal chromosome abnormalities. Prenatal Diagnosis, 7, 623–630.PubMedCrossRef
Borrell, A., Gonce, A., Martinez, J. M., Borobio, V., Fortuny, A., Coll, O., et al. (2005). First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenatal Diagnosis, 25, 901–905.PubMedCrossRef
Boyd, P. A., Devigan, C., Khoshnood, B., Loane, M., Garne, E., Dolk, H., et al. (2008). Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down’s syndrome. British Journal of Obstetrics and Gynaecology, 115(6), 689–696.PubMedCrossRef
Brasington, C. K. (2007). What I wish I knew then...reflections from personal experiences in counseling about Down syndrome. Journal of Genetic Counseling, 16(6), 731–734.PubMedCrossRef
Caughey, A. B., Washington, A. E., & Kuppermann, M. (2008). Perceived risk of prenatal diagnostic procedure-related miscarriage and Down syndrome among pregnant women. American Journal of Obstetrics and Gynecology, 198(3), 333.PubMedCrossRef
Cheffins, T., Chan, A., Haan, E. A., Ranieri, E., Ryall, R. G., Keane, R. J., et al. (2000). The impact of maternal serum screening on the birth prevalence of Down’s syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG, 107(12), 1453–1459.PubMedCrossRef
Chervenak, F. A., McCullough, L. B., & Campbell, S. (1999). Third trimester abortion: is compassion enough? British Journal of Obstetrics and Gynaecology, 106(4), 293–296.PubMedCrossRef
Chitty, L. S., van der Schoot, C. E., Hahn, S., & Avent, N. D. (2008). SAFE–the Special Non-invasive Advances in Fetal and Neonatal Evaluation Network: aims and achievements. Prenatal Diagnosis, 28(2), 83–88.PubMedCrossRef
Cicero, S., Curcio, P., Papageorghiou, A., Sonek, J., & Nicolaides, K. (2001). Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study. Lancet, 358, 1665–1667.PubMedCrossRef
Cleary-Goldman, J., Morgan, M. A., Malone, F. D., Robinson, J. N., D’Alton, M. E., & Schulkin, J. (2006). Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists. Obstetrics and Gynecology, 107, 11–17.CrossRefPubMed
Cowchock, F. S., & Jackson, L. G. (1976). Diagnostic use of maternal serum alpha-fetoprotein levels. Obstetrics and Gynecology, 47(1), 63–68.PubMed
Cuckle, H. S., Wald, N. J., & Lindenbaum, R. H. (1984). Maternal serum alpha fetoprotein measurement. A screening test for Down syndrome. Lancet, 28(1(8383)), 926–929.CrossRef
Cuckle, H. S., Wald, N. J., & Thompson, S. G. (1987). Estimating a woman’s risk of having a pregnancy associated with Down Syndrome using her age and serum alpha-fetoprotein level. British Journal of Obstetrics and Gynaecology, 94, 387.PubMedCrossRef
Dahl, K., Kesmodel, U., Hvidman, L., & Olesen, F. (2006). Informed consent: attitudes, knowledge and information concerning prenatal examinations. Acta Obstetricia et Gynecologica Scandinavica, 85(12), 1414–1419.PubMedCrossRef
Dalgliesh, G. L., Aitken, D. A., Lyall, F., Howatson, A. G., & Connor, J. M. (2001). Placental and maternal serum inhibin-A and activin-A levels in Down’s syndrome pregnancies. Placenta, 22(2–3), 227–234.PubMedCrossRef
Dolk, H., Loane, M., Garne, E., De Walle, H., Queisser-Luft, A., De Vigan, C., et al. (2005). Trends and geographic inequalities in the prevalence of Down syndrome in Europe, 1980–1999. Revue d'Epidemiologie et de Sante Publique, 53 Spec No 2, 2S87–2S95.PubMed
Dommergues, M., Benachi, A., Benifla, J. L., des Noëttes, R., & Dumez, Y. (1999). The reasons for termination of pregnancy in the third trimester. British Journal of Obstetrics and Gynaecology, 106(4), 297–303.PubMedCrossRef
Driscoll, D. A., Gross, S. J., & Professional Practice and Guidelines Committee. (2008). First trimester diagnosis and screening for fetal aneuploidy. Genetics in Medicine, 10(1), 73–75.PubMedPubMedCentralCrossRef
Driscoll, D. A., Morgan, M. A., & Schulkin, J. (2009). Screening for Down syndrome: changing practice of obstetricians. American Journal of Obstetrics and Gynecology, 200(4), 459.PubMedCrossRef
Drotar, D., Baskiewicz, A., Irvin, N., Kennell, J., & Klaus, M. (1975). The adaptation of parents to the birth of an infant with a congenital malformation: a hypothetical model. Pediatrics, 56(5), 710–717.PubMed
Eddleman, K. A., Malone, F. D., Sullivan, L., Dukes, K., Berkowitz, R. L., Kharbutli, Y., et al. (2006). Pregnancy loss rates after midtrimester amniocentesis. Obstetrics and Gynecology, 108(5), 1067–1072.PubMedCrossRef
Egan, J. F., Kaminsky, L. M., DeRoche, M. E., Barsoom, M. J., Borgida, A. F., & Benn, P. A. (2002). Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists. American Journal of Obstetrics and Gynecology, 187(5), 1230–1234.PubMedCrossRef
Egan, J. F., Benn, P. A., Zelop, C. M., Bolnick, A., Gianferrari, E., & Borgida, A. F. (2004). Down syndrome births in the United States from 1989 to 2001. American Journal of Obstetrics and Gynecology, 191(3), 1044–1048.PubMedCrossRef
Fan, H. C., Blumenfield, Y. J., Chitkara, U., Hudgins, L., & Quake, S. R. (2008). Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proceedings of the National Academy of Sciences of the United States of America, 105(42), 16266–16271.PubMedPubMedCentralCrossRef
Finning, K. M., & Chitty, L. S. (2008). Non-invasive fetal sex determination: impact on clinical practice. Semin Fetal Neonatal Med, 13(2), 69–75.PubMedCrossRef
Ford, C., Moore, A. J., Jordan, P. A., Bartlett, W. A., Wyldes, M. P., Jones, A. F., et al. (1998). The value of screening for Down’s syndrome in a socioeconomically deprived area with a high ethnic population. British Journal of Obstetrics and Gynaecology, 105(8), 855–859.PubMedCrossRef
Gans Epner, J. E., Jonas, H. S., & Seckinger, D. L. (1998). Late-term abortion. JAMA, 280, 724–729.CrossRef
Freeman, S. B., Bean, L. H., Allen, E. G., Tinker, S. W., Locke, A. E., Druschel, C., et al. (2008). Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med, 10(3), 173–180.PubMedCrossRef
Georgsson Öhman, S., Saltvedt, S., Waldenström, U., Grunewald, C., & Olin-Lauritzen, S. (2006). Pregnant women’s responses to information about an increased risk of carrying a baby with Down syndrome. Birth, 33(1), 64–73.CrossRef
Gekas, J., Gagné, G., Bujold, E., Douillard, D., Forest, J.-C., Reinharz, D., et al. (2009). Comparison of cost effectiveness of different strategies and risk cut-off values in prenatal screening for Down’s syndrome: computer simulation. BMJ, 338, b138.PubMedPubMedCentralCrossRef
Green, J. M., Hewison, J., Bekker, H. L., Bryant, L. D., & Cuckle, H. S. (2004). Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technology Assessment, 8(33), iii. ix–x, 1–109.PubMedCrossRef
Grimes, D. A., & Snively, G. R. (1999). Patients’ understanding of medical risks: implications for genetic counseling. Obstetrics and Gynecology, 93, 910–914.PubMed
Hall, S., Bobrow, M., & Marteau, T. M. (2000). Psychological consequences for parents of false negative results on prenatal screening for Down’s syndrome: retrospective interview study. BMJ, 320(7232), 407–412.PubMedPubMedCentralCrossRef
Harris, R. A., Washington, A. E., Nease, R. F., Jr., & Kuppermann, M. (2004). Cost utility of prenatal diagnosis and the risk-based threshold. Lancet, 363, 276–282.PubMedCrossRef
Hastings, R. P., & Beck, A. (2004). Practitioner review: stress intervention for parents of children with intellectual disabilities. Journal of Child Psychology and Psychiatry, 45(8), 1338–1349.PubMedCrossRef
Hoskovec, J., Mastrobattista, J. M., Johnston, D., Kerrigan, A., Robbins-Furman, P., & Wicklund, C. A. (2008). Anxiety and prenatal testing: do women with soft ultrasound findings have increased anxiety compared to women with other indications for testing? Prenatal Diagnosis, 28(2), 135–140.PubMedCrossRef
Illanes, S., Denbow, M., Kailasam, C., Finning, K., & Soothill, P. W. (2007). Early detection of cell-free fetal DNA in maternal plasma. Early Human Development, 83, 563–566.PubMedCrossRef
Jackson, L. G., Zachary, J. M., Fowler, S. E., Desnick, R. J., Golbus, M. S., Ledbetter, D. H., et al. (1992). A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. New England Journal of Medicine, 327(9), 594–598.PubMedCrossRef
Khoshnood, B., Pryde, P., Blondel, B., & Lee, K. S. (2003). Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down’s syndrome in the United States. Revue d'Epidemiologie et de Sante Publique, 51(6), 617–627.PubMed
Khoshnood, B., De Vigan, C., Vodovar, V., Goujard, J., & Goffinet, F. (2004). A population-based evaluation of the impact of antenatal screening for Down’s syndrome in France, 1981–2000. BJOG, 111(5), 485–490.PubMedPubMedCentralCrossRef
Kobelka, C., Mattman, A., & Langlois, S. (2009). An evaluation of the decision-making process regarding amniocentesis following a screen-positive maternal serum screen result. Prenatal Diagnosis, 29(5), 514–519.PubMedCrossRef
Korenromp, M. J., Christiaens, G. C., van den Bout, J., Mulder, E. J., Hunfeld, J. A., Bilardo, C. M., et al. (2005). Long-term psychological consequences of pregnancy termination for fetal abnormality: a cross-sectional study. Prenatal Diagnosis, 25(3), 253–260.PubMedCrossRef
Krantz, D. A., Hallahan, T. W., Macri, V. J., & Macri, J. N. (2007). Genetic sonography after first-trimester Down syndrome screening. Ultrasound in Obstetrics and Gynecology, 29(6), 666–670.PubMedCrossRef
Kuppermann, M., Nease, R. F., Learman, L. A., Gates, E., Blumberg, B., & Washington, A. E. (2000). Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women’s preferences. Obstetrics and Gynecology, 96, 511–516.PubMed
Learman, L. A., Kuppermann, M., Gates, E., Nease, R. F., Jr., Gildengorin, V., & Washington, A. E. (2003). Social and familial context of prenatal genetic testing decisions: are there racial/ethnic differences? American Journal of Medical Genetics, 119C, 19–26.PubMedCrossRef
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., et al. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet, 350, 385–487.CrossRef
Lo, Y. M. D., Tsui, N. B. Y., Chiu, R. W. K., Lau, T. K., Leung, T. N., Heung, M. M. S., et al. (2007). Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nature Medicine, 13, 218–223.PubMedCrossRef
Lloyd, T., & Hastings, R. P. (2008). Psychological variables as correlates of adjustment in mothers of children with intellectual disabilities: cross-sectional and longitudinal relationships. Journal of Intellectual Disability Research, 52(Pt 1), 37–48.PubMed
Malone, F. D., Ball, R. H., Nyberg, D. A., Comstock, C. H., Saade, G., Berkowitz, R. L., et al. (2004). First-trimester nasal bone evaluation for aneuploidy in the general population. Obstetrics and Gynecology, 104, 1222–1228.PubMedCrossRef
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., et al. (2005). First-trimester or second-trimester screening, or both, for Down’s syndrome. New England Journal of Medicine, 10;353(19), 2001–2011.CrossRef
Mansfield, C., Hopfer, S., & Marteau, T. M. (1999). Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality). Prenatal Diagnosis, 19(9), 808–812.PubMedCrossRef
Merkatz, I. R., Nitowsky, H. M., Macri, J. N., & Johnson, W. E. (1984). An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. American Journal of Obstetrics and Gynecology, 148(7), 886–894.PubMedCrossRef
Morris, J. K., Mutton, D. E., & Alberman, E. (2005). Recurrences of free trisomy 21: analysis of data from the National Down Syndrome Cytogenetic Register. Prenatal Diagnosis, 25(12), 1120–1128.PubMedCrossRef
Mueller, V. M., Huang, T., Summers, A. M., & Winsor, S. H. (2005). The influence of risk estimates obtained from maternal serum screening on amniocentesis rates. Prenatal Diagnosis, 25(13), 1253–1257.PubMedCrossRef
Mujezinovic, F., & Alfirevic, Z. (2007). Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstetrics and Gynecology, 110, 687–694.PubMedCrossRef
Nagle, C., Hodges, R., Wolfe, R., & Wallace, E. M. (2009). Reporting Down syndrome screening results: women’s understanding of risk. Prenatal Diagnosis, 29(3), 234–239.PubMedCrossRef
Nassar, A. H., Martin, D., Gonzalez-Quintero, V. H., Gomez-Marin, O., Salman, F., Gutierrez, A., et al. (2004). Genetic amniocentesis complications: is the incidence overrated? Gynecologic and Obstetric Investigation, 58(2), 100–104.PubMedCrossRef
National Screening Committee. (2002). Antenatal Screening Service for Down’s Syndrome in England: 2001. Published August 2002, ISBN 0954368401.
Newson, A. J. (2008). Ethical aspects arising from non-invasive fetal diagnosis. Semin Fetal Neonatal Med, 13(2), 103–108.PubMedCrossRef
Nicolaides, K. H., Brizot, M. L., & Snijders, R. J. (1994). Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. British Journal of Obstetrics and Gynaecology, 101(9), 782–786.PubMedCrossRef
Nicolaides, K. H., Spencer, K., Avgidou, K., Faiola, S., & Falcon, O. (2007). Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound in Obstetrics and Gynecology, 25(3), 221–226.CrossRef
Norem, C. T., Schoen, E. J., Walton, D. L., Krieger, R. C., O’Keefe, J., To, T. T., et al. (2005). Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. Obstetrics and Gynecology, 106(4), 747–752.PubMedCrossRef
Paintin, D. (1997). Abortion after 24 weeks. British Journal of Obstetrics and Gynaecology, 104(4), 398–400.PubMedCrossRef
Pelchat, D., Bisson, J., Ricard, N., Perreault, M., & Bouchard, J. M. (1999). Longitudinal effects of an early family intervention programme on the adaptation of parents of children with a disability. International Journal of Nursing Studies, 36, 465–477.PubMedCrossRef
Penrose, L. S. (1933). The relative effects of paternal and maternal age in mongolism. Journal of Genetics, 27, 219.CrossRef
Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Hahn, S. E., Strecker, M. N., et al. (2006). A new definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force report. Journal of Genetic Counseling, 15(2), 77–83.PubMedCrossRef
Royal College of Obstetricians and Gynaecologists report. (1996). Termination of pregnancy for fetal abnormality in England, Wales and Scotland. London: RCOG.
Savva, G. M., Morris, J. K., Mutton, D. E., & Alberman, E. (2006). Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenatal Diagnosis, 26(6), 499–504.PubMedCrossRef
Schieve, L. A., Boulet, S. L., Boyle, C., Rasmussen, S. A., & Schendel, D. (2009). Health of children 3 to 17 years of age with Down syndrome in the 1997–2005 national health interview survey. Pediatrics, 123(2), e253–e260.PubMedCrossRef
Schmitz, D., Netzer, C., & Henn, W. (2009). An offer you can’t refuse? Ethical implications of non-invasive prenatal diagnosis. Nature Reviews Genetics, 10, 515.PubMedCrossRef
Seeds, J. W. (2004) Diagnostic mid trimester amniocentesis: how safe? American Journal of Obstetrics and Gynecology, 191(2), 607–615.PubMedCrossRef
Senat, M. V., Bernard, J. P., Boulvain, M., & Ville, Y. (2003). Intra- and interoperator variability in fetal nasal bone assessment at 11–14 weeks of gestation. Ultrasound in Obstetrics and Gynecology, 22(2), 138–141.PubMedCrossRef
Sharma, G., McCullough, L. B., & Chervenak, F. A. (2007). Ethical considerations of early (first vs. second trimester) risk assessment disclosure for trisomy 21 and patient choice in screening versus diagnostic testing. American Journal of Medical Genetics Part C Seminars in Medical Genetics, 145C, 99–104.CrossRefPubMed
Singer, G. H. S., Marquis, J., Powers, L. K., Blanchard, L., Divenere, N., Santelli, B., et al. (1999). A multi-site evaluation of parent to parent programs for parents of children with disabilities. Journal of Early Intervention, 22, 217–229.CrossRef
Skotko, B. G. (2005). Prenatally diagnosed Down syndrome: mothers who continued their pregnancies evaluate their health care providers. American Journal of Obstetrics and Gynecology, 192(3), 670–677.PubMedCrossRef
Skotko, B., & Bedia, R. C. (2005). Postnatal support for mothers of children with Down syndrome. Mental Retardation, 43(3), 196–212.PubMedCrossRef
mith-Bindman, R., Hosmer, W., Feldstein, V. A., Deeks, J. J., & Goldberg, J. D. (2001). Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis. JAMA, 285(8), 1044–1055.PubMedCrossRef
Smith-Bindman, R., Chu, P., & Goldberg, J. D. (2007). Second trimester prenatal ultrasound for the detection of pregnancies at increased risk of Down syndrome. Prenatal Diagnosis, 27(6), 535–544.PubMedCrossRef
Tabor, A., Philip, J., Madsen, M., Bang, J., Obel, E. B., & Norgaard-Pedersen, B. (1986). Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet, 1(8493), 1287–1293.PubMedCrossRef
van den Berg, M., Timmermans, D. R., Kleinveld, J. H., Garcia, E., van Vugt, J. M., & van der Wal, G. (2005a). Accepting or declining the offer of prenatal screening for congenital defects: test uptake and women’s reasons. Prenatal Diagnosis, 25(1), 84–90.PubMedCrossRef
van den Berg, M., Timmermans, D. R., Ten Kate, L. P., van Vugt, J. M., & van der Wal, G. (2005b). Are pregnant women making informed choices about prenatal screening? Genetics in Medicine, 7(5), 332–338.PubMedCrossRef
Von Eggeling, F., Freytag, M., Fahsold, R., Horsthemke, B., & Claussen, U. (1993). Rapid detection of trysomy 21 by quantitative PCR. Human Genetics, 91(6), 567–570.CrossRef
Wald, N. J., Cuckle, H. S., Densem, J. W., Nanchahal, K., Canick, J. A., Haddow, J. E., et al. (1988). Maternal serum unconjugated oestriol as an antenatal screening test for Down’s syndrome. British Journal of Obstetrics and Gynaecology, 95(4), 334–341.PubMedCrossRef
Wald, N., Stone, R., Cuckle, H. S., Grudzinskas, J. G., Barkai, G., Brambati, B., et al. (1992). First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down’s syndrome. BMJ, 305, 28.PubMedPubMedCentralCrossRef
Wald, N. J., Huttly, W. J., & Hennessy, C. F. (1999). Down’s syndrome screening in the UK in 1998. Lancet, 354(9186), 1264.PubMedCrossRef
Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM; SURUSS Research Group. (2003). First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technology Assessment Vol. 7: No. 11.
Wald, N. J., Rodeck, C., Hackshaw, A. K., & Rudnicka, A. (2004) SURUSS in perspective. British Journal of Obstetrics and Gynaecology, 111, 521–531.PubMedCrossRef
Wald, N. J., Bestwick, J. P., & Morris, J. K. (2006). Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenatal Diagnosis, 26(6), 514–523.PubMedCrossRef
Wald, N. J., Huttly, W. J., Murphy, K. W., Ali, K., Bestwick, J. P., & Rodeck, C. H. (2009). Antenatal screening for Down’s syndrome using the integrated test at two London hospitals. Journal of Medical Screening, 16(1), 7–10.PubMedCrossRef
Warburton, D., Dallaire, L., Thangavelu, M., Ross, L., Levin, B., & Kline, J. (2004). Trisomy recurrence: a reconsideration based on North American data. American Journal of Human Genetics, 75(3), 376–385.PubMedPubMedCentralCrossRef
Weinans, M. J., Kooij, L., Müller, M. A., Bilardo, K. M., Van Lith, J. M., & Tymstra, T. (2004). A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study. Prenatal Diagnosis, 24(5), 347–351.PubMedCrossRef
Wright, D. E., & Bradbury, I. (2005). Repeated measures screening for Down’s syndrome. British Journal of Obstetrics and Gynaecology, 112(1), 80–83.PubMedCrossRef
Wright, C. F., & Burton, H. (2009). The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update, 15(1), 139–151.PubMedCrossRef
Wright, D., Bradbury, I., Benn, P., Cuckle, H., & Ritchie, K. (2004). Contingent screening for Down’s syndrome is an efficient alternative to non-disclosure sequential screening. Prenatal Diagnosis, 24, 762–766.PubMedCrossRef
Zikmund-Fisher, B. J., Fagerlin, A., Keeton, K., & Ubel, P. A. (2007). Does labeling prenatal screening test results as negative or positive affect a woman’s responses? American Journal of Obstetrics and Gynecology, 197(5), 528.PubMedPubMedCentralCrossRef
Metadata
Title
Prenatal Testing for Down Syndrome: Comparison of Screening Practices in the UK and USA
Author
Dagmar Tapon
Publication date
01-04-2010
Publisher
Springer US
Published in
Journal of Genetic Counseling / Issue 2/2010
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-009-9269-1

Other articles of this Issue 2/2010

Journal of Genetic Counseling 2/2010 Go to the issue

Announcement

Diplomates Certified in 2009

Original Research

Long-term Evaluation of Genetic Counseling Following False-Positive Newborn Screen for Cystic Fibrosis

Book Review

Doris Teichler Zallen, To Test or Not To Test: A Guide to Genetic Screening and Risk

Original Research

Examining the Relationship Between Genetic Counselors’ Attitudes Toward Deaf People and the Genetic Counseling Session

Original Research

Efficacy of the Health Belief Model for Predicting Intention to Pursue Genetic Testing for Colorectal Cancer

Original Research

Genetic Counselors’ Perceived Responsibilities Regarding Reproductive Issues for Patients at Risk for Huntington Disease